Antihuman factor VIII C2 domain antibodies in hemophilia A mice recognize a functionally complex continuous spectrum of epitopes dominated by inhibitors of factor VIII activation.
The diversity of factor VIII (fVIII) C2 domain antibody epitopes was investigated by competition enzyme-linked immunosorbent assay (ELISA) using a panel of 56 antibodies. The overlap patterns produced 5 groups of monoclonal antibodies (MAbs), designated A, AB, B, BC, and C, and yielded a set of 18 distinct epitopes. Group-specific loss of antigenicity was associated with mutations at the Met2199/Phe2200 phospholipid binding beta-hairpin (group AB MAbs) and at Lys2227 (group BC MAbs), which allowed orientation of the epitope structure as a continuum that covers one face of the C2 beta-sandwich. MAbs from groups A, AB, and B inhibit the binding of fVIIIa to phospholipid membranes. Group BC was the most common group and displayed the highest specific fVIII inhibitor activities. MAbs in this group are type II inhibitors that inhibit the activation of fVIII by either thrombin or factor Xa and poorly inhibit the binding of fVIII to phospholipid membranes or von Willebrand factor (VWF). Group BC MAbs are epitopically and mechanistically distinct from the extensively studied group C MAb, ESH8. These results reveal the structural and functional complexity of the anti-C2 domain antibody response and indicate that interference with fVIII activation is a major attribute of the inhibitor landscape.
Meeks
Shannon L
SL
Aflac Cancer Center and Blood Disorders Service, Children's Healthcare of Atlanta, Department of Pediatrics, Emory University, Atlanta, GA, USA.
Healey
John F
JF
Parker
Ernest T
ET
Barrow
Rachel T
RT
Lollar
Pete
P
D000818:Animals; D000911:Antibodies, Monoclonal / Q000276:immunology*; D004797:Enzyme-Linked Immunosorbent Assay; D018604:Epitope Mapping / Q000379:methods*; D000939:Epitopes / Q000276:immunology*; D005169:Factor VIII / Q000037:antagonists & inhibitors / Q000737:chemistry / Q000276:immunology*; D015944:Factor VIIIa / Q000037:antagonists & inhibitors*; D006467:Hemophilia A / Q000276:immunology*; D006801:Humans; D051379:Mice; D010743:Phospholipids / Q000378:metabolism; D014841:von Willebrand Factor / Q000378:metabolism
D000911:Antibodies, Monoclonal; D000939:Epitopes; D010743:Phospholipids; D014841:von Willebrand Factor; D015944:Factor VIIIa; C078147:F8 protein, human; D005169:Factor VIII